| HU group (n = 61) | NU group (n = 141) | p |
Known hypertension, n (%) | 47 (77.0) | 100 (70.9) | 0.467 |
Associated cardiovascular risk factors, n (%) |
|
|
|
- diabetes | 8 (13.1) | 13 (9.2) | 0.219 |
- glucose intolerance | 7 (11.5) | 8 (5.7) | 0.071 |
- dyslipidemia | 28 (45.9) | 60 (44.7) | 0.873 |
- overweight/obesity | 42 (68.8) | 65 (46.1) | 0.003 |
- abdominal obesity | 38 (62.3) | 96 (68.1) | 0.424 |
- metabolic syndrome | 26 (42.6) | 55 (39.0) | 0.021 |
- tobacco use | 4 (6.5) | 9 (6.4) | 1 |
Factors predisposing with the hyperuricemia, n (%) |
|
|
|
- neoplasia | 2 (3.3) | 0 (0) | 0.031 |
- chemotherapy | 1 (0.7) | 0 (0) | 0.127 |
- alcohol consumption | 17 (27.8) | 51 (36.2) | 0.325 |
Complications of hypertension, n (%) |
|
|
|
- left ventricular hypertrophy | 12 (19.7) | 16 (11.3) | 0.181 |
- heart failure | 19 (31.0) | 35 (25.0) | 0.131 |
- stroke | 5 (8.0) | 44 (31.0) | 0.071 |
- renal insufficiency | 33 (54.0) | 62 (44.0) | 0.098 |
Therapeutic classes used, n (%) |
|
|
|
- thiazides | 44 (72.1) | 67 (47.5) | 0.002 |
- calcium antagonists | 42 (68.8) | 96 (68.1) | 1 |
- ACEi/ARBs | 40 (65.6) | 89 (63.1) | 0.862 |
- betablockers | 16 (26.2) | 21 (14.9) | 0.086 |
- spironolactone | 4 (6.6) | 3 (2.1) | 0.092 |
Controlled hypertension, n (%) | 19 (31.2) | 72 (51.1) | 0.01 |